Is target trial emulation as good as a randomised trial?

No. It removes several design-induced biases but cannot balance unmeasured factors, which is what randomisation does.

What is immortal time bias?

A period during which the outcome could not have occurred being assigned to the treatment group, making the treatment appear protective for arithmetical reasons.

Why is it being used for GLP-1 questions?

Cardiovascular and kidney outcome questions would need enormous, decade-long trials. Emulation offers earlier answers from existing data.

Research & Regulatory News

Target Trial Emulation: Making Observational Data Behave

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-232 cited sources

Target trial emulation is a method for analysing observational data by first specifying the randomised trial you would have run, then reproducing its design as closely as the data allows. It removes several classic biases and cannot remove confounding by unmeasured factors.

Key facts

Applies to: Routine records, claims, registries
Core step: Specify the hypothetical trial first
Fixes: Immortal time bias, prevalent user bias
Does not fix: Unmeasured confounding
GLP-1 example: Tang 2025 (PMID 40874398)
Tirzepatide example: Lin 2025 (PMID 40368924)

The problem it addresses

Observational analyses of health records are cheap, large and fast, and they are riddled with biases that arise from how the analysis is set up rather than from the data itself. The most common is immortal time bias — where a period during which an outcome could not have occurred gets assigned to the treatment group, making the treatment look protective for arithmetical reasons.

How the method works

Write down the trial you would run — eligibility, treatment strategies, assignment, follow-up start, outcome, analysis plan — before touching the data. Then construct the analysis so each element is matched as closely as the records permit. Specifying the design in advance is what prevents the analytical choices from being made after seeing which ones produce a result.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

Why the alignment of time zero is the crux

In a real trial, eligibility, assignment and the start of follow-up happen at one moment. In records they are scattered, and analysts routinely misalign them without noticing. Forcing them to coincide is the single change that eliminates most of the bias, and it is the discipline the framework really imposes.

What it still cannot do

Randomise. Emulation controls for what was recorded; it cannot balance what was not. If people prescribed a drug differ systematically from those who were not in some way absent from the records — motivation, unrecorded severity, access — the comparison remains confounded no matter how carefully the design is emulated.

Why it matters for obesity medicine specifically

The cardiovascular and kidney questions being asked about incretins would require enormous, decade-long randomised trials. Emulation offers earlier answers from data that already exists, which is genuinely valuable. It also means a growing share of what gets reported as GLP-1 outcome evidence is not from randomised trials at all, and readers should know which they are looking at.

How to read one

Check whether the target trial is actually specified in the paper. Check where time zero sits. Check which confounders were available and, more importantly, which were not. A well-conducted emulation states its own limitations plainly; the reporting that follows it usually does not.

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is target trial emulation as good as a randomised trial?: No. It removes several design-induced biases but cannot balance unmeasured factors, which is what randomisation does.
What is immortal time bias?: A period during which the outcome could not have occurred being assigned to the treatment group, making the treatment appear protective for arithmetical reasons.
Why is it being used for GLP-1 questions?: Cardiovascular and kidney outcome questions would need enormous, decade-long trials. Emulation offers earlier answers from existing data.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum